Disease-associated inflammatory biomarker profiles in blood in different subtypes of multiple sclerosis: Prospective clinical and MRI follow-up study

Journal of Neuroimmunology

Volumn 234, Issue 1-2, 2011, Pages 141-147

  Hagman, Sanna ^a   Raunio, Minna ^b   Rossi, Maija ^b   Dastidar, Prasun ^b   Elovaara, Irina ^a,b  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Apoptosis; Biomarkers; Chemokines; Cytokines; Expanded disability status scale; Magnetic resonance imaging; Multiple sclerosis

Indexed keywords

FAS ANTIGEN; MACROPHAGE INFLAMMATORY PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; IMAGE PROCESSING; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; UPREGULATION;

ADULT; AGED; APOPTOSIS; BIOLOGICAL MARKERS; BRAIN; CYTOKINES; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC;

EID: 79955673049     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.02.009     Document Type: Article

References (51)

1. Achiron A., Barak Y. Multiple sclerosis - from probable to definite diagnosis: a 7-year prospective study. Arch. Neurol. 2000, 57:974-979.
2. Afzali B., Mitchell P., Lechler R.I., John S., Lombardi G. Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells. Clin. Exp. Immunol. 2010, 159:120-130.
3. Aktas O., Prozorovski T., Zipp F. Death ligands and autoimmune demyelination. Neuroscientist 2006, 12:305-316.
4. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr. Opin. Neurol. 2002, 15:239-245.
5. Bernhagen J., Krohn R., Lue H., Gregory J.L., Zernecke A., Koenen R.R., Dewor M., Georgiev I., Schober A., Leng L., Kooistra T., Fingerle-Rowson G., Ghezzi P., Kleemann R., McColl S.R., Bucala R., Hickey M.J., Weber C. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 2007, 13:587-596.
6. Bonetti B., Raine C.S. Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann. Neurol. 1997, 42:74-84.
7. Boylan M.T., Crockard A.D., McDonnell G.V., McMillan S.A., Hawkins S.A. Serum and cerebrospinal fluid soluble Fas levels in clinical subgroups of multiple sclerosis. Immunol. Lett. 2001, 78:183-187.
8. Bradl M., Lassmann H. Progressive multiple sclerosis 2009, Semin. Immunopathol.
9. Brex P.A., Ciccarelli O., O'Riordan J.I., Sailer M., Thompson A.J., Miller D.H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. 2002, 346:158-164.
10. Calandra T., Bernhagen J., Mitchell R.A., Bucala R. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J. Exp. Med. 1994, 179:1895-1902.
11. Cannella B., Gaupp S., Omari K.M., Raine C.S. Multiple sclerosis: death receptor expression and oligodendrocyte apoptosis in established lesions. J. Neuroimmunol. 2007, 188:128-137.
12. Cepok S., Schreiber H., Hoffmann S., Zhou D., Neuhaus O., von Geldern G., Hochgesand S., Nessler S., Rothhammer V., Lang M., Hartung H.P., Hemmer B. Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis. Arch. Neurol. 2009, 66:1216-1223.
13. Ciusani E., Frigerio S., Gelati M., Corsini E., Dufour A., Nespolo A., La Mantia L., Milanese C., Massa G., Salmaggi A. Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 1998, 82:5-12.
14. Comi C., Leone M., Bonissoni S., DeFranco S., Bottarel F., Mezzatesta C., Chiocchetti A., Perla F., Monaco F., Dianzani U. Defective T cell fas function in patients with multiple sclerosis. Neurology 2000, 55:921-927.
15. Denkinger C.M., Denkinger M., Kort J.J., Metz C., Forsthuber T.G. In vivo blockade of macrophage migration inhibitory factor ameliorates acute experimental autoimmune encephalomyelitis by impairing the homing of encephalitogenic T cells to the central nervous system. J. Immunol. 2003, 170:1274-1282.
16. Dowling P., Shang G., Raval S., Menonna J., Cook S., Husar W. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J. Exp. Med. 1996, 184:1513-1518.
17. D'Souza S.D., Bonetti B., Balasingam V., Cashman N.R., Barker P.A., Troutt A.B., Raine C.S., Antel J.P. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J. Exp. Med. 1996, 184:2361-2370.
18. Fassbender K., Ragoschke A., Rossol S., Schwartz A., Mielke O., Paulig A., Hennerici M. Increased release of interleukin-12p40 in MS: association with intracerebral inflammation. Neurology 1998, 51:753-758.
19. Fisniku L.K., Brex P.A., Altmann D.R., Miszkiel K.A., Benton C.E., Lanyon R., Thompson A.J., Miller D.H. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008, 131:808-817.
20. Fox R.J., Kivisakk P., Fisher E., Tucky B., Lee J.C., Rudick R.A., Ransohoff R.M. Multiple sclerosis: chemokine receptor expression on circulating lymphocytes in correlation with radiographic measures of tissue injury. Mult. Scler. 2008, 14:1036-1043.
21. Frischer J.M., Bramow S., Dal-Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
22. Harris V.K., Sadiq S.A. Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol. Diagn. Ther. 2009, 13:225-244.
23. Hawker K., O'Connor P., Freedman M.S., Calabresi P.A., Antel J., Simon J., Hauser S., Waubant E., Vollmer T., Panitch H., Zhang J., Chin P., Smith C.H., OLYMPUS trial group Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann. Neurol. 2009, 66:460-471.
24. Heinonen T., Dastidar P., Kauppinen P., Malmivuo J., Eskola H. Semi-automatic tool for segmentation and volumetric analysis of medical images. Med. Biol. Eng. Comput. 1998, 36:291-296.
25. Heinonen T., Dastidar P., Eskola H., Frey H., Ryymin P., Laasonen E. Applicability of semi-automatic segmentation for volumetric analysis of brain lesions. J. Med. Eng. Technol. 1998, 22:173-178.
26. Hohnoki K., Inoue A., Koh C.S. Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. J. Neuroimmunol. 1998, 87:27-32.
27. Imitola J., Chitnis T., Khoury S.J. Cytokines in multiple sclerosis: from bench to bedside. Pharmacol. Ther. 2005, 106:163-177.
28. Kithcart A.P., Cox G.M., Sielecki T., Short A., Pruitt J., Papenfuss T., Shawler T., Gienapp I., Satoskar A.R., Whitacre C.C. A small-molecule inhibitor of macrophage migration inhibitory factor for the treatment of inflammatory disease. FASEB J. 2010, 24:4459-4466.
29. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
30. Lassmann H., Bruck W., Lucchinetti C.F. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007, 17:210-218.
31. Lopatinskaya L., Zwemmer J., Uitdehaag B., Lucas K., Polman C., Nagelkerken L. Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10years. Mult. Scler. 2006, 12:704-709.
32. Mahad D.J., Ransohoff R.M. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin. Immunol. 2003, 15:23-32.
33. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 2001, 50:121-127.
34. McFarland H.F. Examination of the role of magnetic resonance imaging in multiple sclerosis: a problem-orientated approach. Ann. Indian. Acad. Neurol. 2009, 12:254-263.
35. McQualter J.L., Bernard C.C. Multiple sclerosis: a battle between destruction and repair. J. Neurochem. 2007, 100:295-306.
36. Niino M., Ogata A., Kikuchi S., Tashiro K., Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behcet's disease. J. Neurol. Sci. 2000, 179:127-131.
37. Pender M.P. Treating autoimmune demyelination by augmenting lymphocyte apoptosis in the central nervous system. J. Neuroimmunol. 2007, 191:26-38.
38. Petereit H.F., Pukrop R., Fazekas F., Bamborschke S.U., Ropele S., Kolmel H.W., Merkelbach S., Japp G., Jongen P.J., Hartung H.P., Hommes O.R. Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis. J. Neurol. Sci. 2003, 206:209-214.
39. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P., Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O'Connor P.W., Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann. Neurol. 2005, 58:840-846.
40. Rinta S., Kuusisto H., Raunio M., Paalavuo R., Levula M., Lehtimaki T., Elovaara I. Apoptosis-related molecules in blood in multiple sclerosis. J. Neuroimmunol. 2008, 205:135-141.
41. Sellebjerg F., Krakauer M., Hesse D., Ryder L.P., Alsing I., Jensen P.E., Koch-Henriksen N., Svejgaard A., Soelberg Sorensen P. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur. J. Neurol. 2009, 16:1291-1298.
42. Selmaj K., Raine C.S., Cannella B., Brosnan C.F. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 1991, 87:949-954.
43. Sharief M.K. Impaired Fas-independent apoptosis of T lymphocytes in patients with multiple sclerosis. J. Neuroimmunol. 2000, 109:236-243.
44. Sharief M.K., Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 1991, 325:467-472.
45. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
46. Szczucinski A., Losy J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets new therapies. Acta Neurol. Scand. 2007, 115:137-146.
47. Tomassini V., Palace J. Multiple sclerosis lesions: insights from imaging techniques. Expert Rev. Neurother. 2009, 9:1341-1359.
48. Tumani H., Hartung H.P., Hemmer B., Teunissen C., Deisenhammer F., Giovannoni G., Zettl U.K., Group BioMS Study Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol. Dis. 2009, 35:117-127.
49. Watzlawik J., Warrington A.E., Rodriguez M. Importance of oligodendrocyte protection. BBB breakdown inflammation remyelination. Expert Rev. Neurother 2010, 10:441-457.
50. Zipp F. Apoptosis in multiple sclerosis. Cell Tissue Res. 2000, 301:163-171.
51. Zipp F., Weller M., Calabresi P.A., Frank J.A., Bash C.N., Dichgans J., McFarland H.F., Martin R. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann. Neurol. 1998, 43:116-120.